Handelsbanken Fonder AB Buys 6,100 Shares of Revvity, Inc. (NYSE:RVTY)

Handelsbanken Fonder AB increased its stake in shares of Revvity, Inc. (NYSE:RVTY) by 23.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 32,360 shares of the company’s stock after purchasing an additional 6,100 shares during the quarter. Handelsbanken Fonder AB’s holdings in Revvity were worth $4,134,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Janus Henderson Group PLC increased its position in Revvity by 3.9% during the first quarter. Janus Henderson Group PLC now owns 5,664,528 shares of the company’s stock valued at $594,769,000 after acquiring an additional 210,100 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Revvity by 18.5% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,126,271 shares of the company’s stock valued at $223,258,000 after purchasing an additional 332,632 shares during the last quarter. EdgePoint Investment Group Inc. purchased a new stake in shares of Revvity in the second quarter worth approximately $209,221,000. Northern Trust Corp bought a new stake in shares of Revvity during the 4th quarter worth approximately $127,401,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Revvity by 5.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,149,122 shares of the company’s stock valued at $120,506,000 after acquiring an additional 57,656 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Trading Down 0.4 %

NYSE RVTY opened at $122.03 on Wednesday. The firm has a market cap of $15.06 billion, a PE ratio of 100.85, a price-to-earnings-growth ratio of 2.90 and a beta of 1.05. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $128.15. The company has a quick ratio of 1.98, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a 50 day moving average price of $121.68 and a 200 day moving average price of $112.01.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The firm had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. During the same quarter last year, the firm earned $1.21 EPS. The business’s quarterly revenue was down 2.5% on a year-over-year basis. As a group, sell-side analysts forecast that Revvity, Inc. will post 4.75 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.23%. The ex-dividend date is Friday, October 18th. Revvity’s payout ratio is currently 23.14%.

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the transaction, the insider now owns 33,400 shares in the company, valued at approximately $3,936,524. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on RVTY shares. Barclays lifted their target price on Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 30th. Wells Fargo & Company initiated coverage on shares of Revvity in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 target price on the stock. Leerink Partners began coverage on shares of Revvity in a research note on Monday, July 8th. They set an “outperform” rating and a $125.00 price target for the company. TD Cowen increased their price objective on Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, Citigroup lifted their target price on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Eight investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Revvity currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.53.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.